Genzyme Announces Return to Full Supply of Thyrogen (thyrotropin alfa for injection)

  Genzyme Announces Return to Full Supply of Thyrogen (thyrotropin alfa for

Business Wire

CAMBRIDGE, Mass. -- November 13, 2012

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that
due to the continued progress in its manufacturing operations this year, its
supply of Thyrogen^® (thyrotropin alfa for injection) has been fully restored.
As a result, beginning in November, Genzyme is able to supply all patient
demand globally.

“We are grateful to the Thyroid cancer treatment community for its ongoing
patience and partnership,” said Genzyme’s Vice President and General Manager
of Endocrinology, Alicia Secor. “Genzyme continues to invest in our
manufacturing capabilities and we are dedicated to delivering high quality
product and continuous supply of Thyrogen for the long term.”

Health care providers should acquire Thyrogen through normal distribution
channels to schedule any new Thyrogen treatments.

About Thyrogen

Thyrogen (thyrotropin alfa for injection) is for patients with
well-differentiated thyroid cancer. Thyrogen is approved as an adjunctive
diagnostic tool for serum thyroglobulin (Tg) testing with or without
radioiodine imaging. Thyrogen is also approved in the U.S. and Europe as an
adjunctive treatment for radioiodine ablation of thyroid tissue remnants in
patients who have undergone a near total or total thyroidectomy for
well-differentiated thyroid cancer and who do not have evidence of metastatic
thyroid cancer.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at

Genzyme^® and Thyrogen^® are registered trademarks of Genzyme Corporation. All
rights reserved.

Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimatesand their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
futurefinancial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans” and similar expressions. Although
Sanofi’s management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of guarantee
that the products candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives, the
Group’s ability to benefit from external growth opportunities as well as those
discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December31, 2010. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.


Lori Gorski, 617-768-9344
Press spacebar to pause and continue. Press esc to stop.